We are live on ! Find out more
CANF icon

Can-Fite BioPharma American Depositary Shares
CANF

6 hedge funds and large institutions have $1.5M invested in Can-Fite BioPharma American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more capital inflows, than outflows

Capital inflows: $72.1K | Capital outflows: $41.2K

0% more funds holding

Funds holding: 6 → 6 (0)

0% less ownership

Funds ownership: 0.3% → 0.3% (-0%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$51.5K
2
Virtu Financial
Virtu Financial
New York
+$20.6K

Top Sellers

Rank Fund Capital Flow
1
Psagot Value Holdings
Psagot Value Holdings
Israel
-$30.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$10.3K

CANF Hedge Fund Activity: Q3 2017 in Review

6 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2017, worth a combined $1.5M — down 6.6% from $1.61M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CANF positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $51.5K. The largest seller was Psagot Value Holdings, cutting an estimated $30.9K.

  • 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $1.5M of Can-Fite BioPharma American Depositary Shares stock for Q3 2017, down 6.6% quarter-over-quarter.
  • 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2017 and 0 closed out, a net change of +1 holder.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2017 was Morgan Stanley, an estimated $51.5K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2017 was Psagot Value Holdings, an estimated $30.9K sold.

Based on aggregated 13F filings for Q3 2017.